To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.
Key claim: HR9421 would prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the state where the patient resides.
Abstract
(HR9421 · 119th Congress) Latest action (2026-06-24): Referred to the House Committee on Energy and Commerce.
Why this matters
In-person visit and in-state licensure requirements would functionally eliminate the telehealth pathway that has become the dominant route for medication abortion since the FDA relaxed REMS in-person dispensing rules. The practical effect falls hardest on patients in states without local abortion providers, rural patients, and those relying on shield-law prescribers in other states. It reframes an ongoing contested question about federal REMS authority versus state medical licensure as a tool for restricting cross-state reproductive care.